Treatment of human prostate cancer cells, which highly express Hsp27, with atractylenolide I has been reported to suppress Hsp27 expression, thereby reducing cell viability and inducing apoptosis [20]. This evidence concerns the gene HSPB1 and prostate carcinoma.